MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

40.04 -1.55

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

39.85

Max

41.09

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+30.09% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	-44M 3.2B
Eelmine avamishind	41.59
Eelmine sulgemishind	40.04

Uudiste sentiment

By Acuity

50%

159 / 361 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. jaan 2026, 23:29 UTC

Kuumad aktsiad

Stocks to Watch: Atossa Therapeutics, Union Pacific

16. jaan 2026, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16. jaan 2026, 22:43 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16. jaan 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

16. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Auto & Transport Roundup: Market Talk

16. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. jaan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

16. jaan 2026, 21:48 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16. jaan 2026, 21:41 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16. jaan 2026, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16. jaan 2026, 21:30 UTC

Omandamised, ülevõtmised, äriostud

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16. jaan 2026, 20:44 UTC

Tulu

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16. jaan 2026, 20:42 UTC

Market Talk

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16. jaan 2026, 20:28 UTC

Market Talk

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16. jaan 2026, 19:12 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16. jaan 2026, 18:53 UTC

Market Talk

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16. jaan 2026, 18:41 UTC

Market Talk

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16. jaan 2026, 18:31 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16. jaan 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

16. jaan 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

16. jaan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

16. jaan 2026, 17:03 UTC

Market Talk

Global Equities Roundup: Market Talk

16. jaan 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16. jaan 2026, 16:32 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16. jaan 2026, 16:20 UTC

Market Talk

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

30.09% tõus

12 kuu keskmine prognoos

Keskmine 54.09 USD 30.09%

Kõrge 62 USD

Madal 44 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

159 / 361 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.